YJU2

Across TCGA pan-cancer cohorts, YJU2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YJU2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher YJU2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YJU2 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

OV, LIHC, and STAD are the cancer types where YJU2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.279	0.691	.002	24	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
BLCA	OS	Median	III,IV	0.239	0.683	.032	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.221	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YJU2–OV (OS)

Open the OV breakdown →